Dentists in Rupert, ID Accepting Medicare
8 Dentists found. Showing 1 - 8
 Dr. Gerald A Woodworth, D.M.D. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 301 Scott Ave, Rupert, ID 83350 Phone: 208-436-6406 Fax: 208-436-9678 |
Dr. John R Garrard, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 301 Scott Ave, Rupert, ID 83350 Phone: 208-436-6406 Fax: 208-436-9678 |
Neal Johnson, D.M.D. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 115 W 100 S, Rupert, ID 83350 Phone: 208-436-4532 Fax: 208-436-0347 |
John Arthur Simpson, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 502 8th St, Rupert, ID 83350 Phone: 208-436-4747 Fax: 208-436-9683 |
Nathan A Catmull, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 502 8th St, Rupert, ID 83350 Phone: 208-436-4747 Fax: 208-436-9683 |
Dr. Charle A Warren, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 301 Scott Ave, Rupert, ID 83350 Phone: 208-436-6406 Fax: 208-436-9678 |
Marcus E Peterson, DDS Dentist Medicare: Medicare Enrolled Practice Location: 402 6th St, Rupert, ID 83350 Phone: 208-650-7941 Fax: 208-436-0735 |
Dr. Robert P Wayment, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 301 Scott Ave, Ste#3, Rupert, ID 83350 Phone: 208-436-6406 Fax: 208-436-9678 |
News Archive
New biomarker may help better predict outcomes in patients with HPV-related head and neck cancers
By analyzing variations in the level of human papillomavirus (HPV) in head and neck cancers, researchers at The University of Texas MD Anderson Cancer Center have discovered a gene signature associated with treatment response and survival in patients.
Breast cancer screening benefits women up to the age of 75
Breast cancer screening is effective, appropriate and reduces deaths from the disease in women aged up to 75 years old according to new research in over 860,000 women aged 70-75 presented today (Friday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin.
Phase 1 clinical trial of OXY111A initiated
NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.
First-ever phase 1 clinical trial of rectal HIV-prevention drug
A topically applied microbicide gel containing a potent anti-HIV drug has been found to significantly reduce infection when applied to rectal tissue that was subsequently exposed to HIV in the laboratory, according to a new study by the UCLA AIDS Institute.
› Verified 1 days ago